Physician profile
Timothy Mcpherson
NPI 1245264696
$13,941.52
in general payments reported to CMS, 2019-2025
45 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,144 · 2020: $1,965 · 2021: $2,312 · 2022: $1,767 · 2023: $1,812 · 2024: $1,789 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,659 · Education: $95.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,659.15 |
| Education | $95.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,664.77 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,231.15 | 2019-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,160.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $989.71 | 2019-2025 | |
| Amgen INC. | $786.13 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $662.51 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $652.89 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $613.52 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.39 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $559.37 | 2019-2025 | Spravato |
| Lilly USA, LLC | $485.78 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $466.21 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $427.96 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $409.85 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $309.54 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mcpherson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.